Financial Daily from THE HINDU group of publications
Tuesday, Dec 17, 2002

Port Info

Group Sites

Corporate - Mergers & Acquisitions

Orchid acquires Mano Pharma

Our Bureau

CHENNAI, Dec. 16

ORCHID Chemicals and Pharmaceuticals Ltd announced the decision to acquire the Chennai-based formulations company, Mano Pharmaceuticals, and its sister company, Sali Healthcare, on a cash deal of Rs 26 crore.

According to an Orchid press release, the acquisition will include the takeover of assets, brands, business and plant of Mano Pharmaceuticals and Sali Healthcare.

The two companies specialise in manufacturing neuro-psychiatry, cardiovascular and anti-diabetic drugs. During the first 11 months of calendar year 2002 the companies together made turnover of Rs 28 crore.

Mano has an all-India field force of 350 personnel catering to the specialist medical community. It also has an ISO 9002 certified manufacturing plant at Chennai.

Send this article to Friends by E-Mail
Comment on this article to

Stories in this Section
Ranbaxy to gain royalty from Bayer for Cipro

Polaris chief held in Jakarta — Business trip goes sour
SC judgment on limited mobility today
Jindal Steel bags energy award
Bangur group cos may take stake in sugar unit
Orchid acquires Mano Pharma
TI Cycles to set up plant at Noida
Pivotal opens centre in India
BHEL plans tie-up with IT major
Balaji Tele MoU with Indonesian co for serial rights
`India has the potential of becoming a developed nation'
Taj joins consortium bidding for AAI land
Tata Coffee to pick up Barista shares
Reliance pegs subscription base at 6 m in first year — LG, Samsung hope to liven up CDMA market
Cochin Intl Airport may post Rs 2-cr profit
Tata debuts in sedan segment with Indigo — Formal launch tomorrow
Volvo launches new tipper truck
Wipro's Light Show

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | Home |

Copyright 2002, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line